Objectif
Despite dramatic advances in molecular and imaging technologies, there are currently no effective pharmacological treatments for the core symptoms of autism spectrum disorder (ASD). Major obstructions to this include a lack of aetiologically-driven or pathophysiologically-accurate animal models; an absence of tests that indicate efficacy; and reliance of clinical trials on DSM/ICD10 categories which provide a collection of biologically heterogeneous patients. Further, even if novel treatments are developed there is no EU platform to clinically test them. Our hypothesis is that a focus on cross-species endophenotypes, finding biologically-homogenous groups of patients, and developing a clinical research network will overcome the limitations in target identification, early triage and clinical trials. Hence, leading European institutions and three SMEs will partner with the EFPIA to: a) develop in vitro models, and animal models that carry confirmed genetic risks, and in these animals to focus on cross-species endophenotypes (e.g. cognitive function, electrophysiology) to facilitate new drug discovery; b) validate the use of sMRI and fMRI-based endophenotypes in genetically-selected healthy volunteers, infants at risk for ASD, and children and adults (including twins) with and without ASD, as early and surrogate markers for efficacy; and to combine this with PET approaches to provide guidance regarding optimal clinical trial design; and c) identify biomarkers that can be used to stratify patients within an umbrella DSM-diagnosis, thus allowing for targeted clinical trials, individualized treatment and back-translation of subgroup-specific biomarkers into preclinical drug discovery. To increase the chance of a breakthrough we will implement new analytical approaches (e.g. support vector machine learning algorithms) and will actively collaborate with patient groups and other international efforts (e.g. the Autism Genetic Resource Exchange (AGRE)).
Champ scientifique
- medical and health sciencesbasic medicinepharmacology and pharmacydrug discovery
- natural sciencesbiological sciencesneurobiologycognitive neuroscience
- medical and health sciencesbasic medicinepharmacology and pharmacypharmaceutical drugs
- natural sciencescomputer and information sciencesartificial intelligencemachine learning
Appel à propositions
IMI-JU-03-2010
Voir d’autres projets de cet appel
Régime de financement
JTI-CP-IMI - Joint Technology Initiatives - Collaborative Project (IMI)Coordinateur
4070 Basel
Suisse
Voir sur la carte
Participants (26)
WC2R 2LS London
Voir sur la carte
68159 Mannheim
Voir sur la carte
6525 XZ Nijmegen
Voir sur la carte
CB2 1TN Cambridge
Voir sur la carte
Participation terminée
101 Reykjavik
Voir sur la carte
3584 CX Utrecht
Voir sur la carte
4051 Basel
Voir sur la carte
75724 Paris
Voir sur la carte
Participation terminée
80333 Muenchen
Voir sur la carte
80539 Munchen
Voir sur la carte
69117 Heidelberg
Voir sur la carte
Participation terminée
2750 Ballerup
Voir sur la carte
17177 Stockholm
Voir sur la carte
RG21 4FA Basingstoke
Voir sur la carte
2340 Beerse
Voir sur la carte
91190 GIF-SUR-YVETTE
Voir sur la carte
1752 Villars-sur-Glâne
Voir sur la carte
WC1E 7HX London
Voir sur la carte
00128 Roma
Voir sur la carte
08540 Princeton Nj
Voir sur la carte
CT13 9NJ Sandwich
Voir sur la carte
75015 PARIS 15
Voir sur la carte
89081 Ulm
Voir sur la carte
6709 PA Wageningen
Voir sur la carte
101 Reykjavik
Voir sur la carte
75008 Paris
Voir sur la carte